Payment overview · 2025
General Payments
$694.88
29 reported records · 15 companies
Healthcare provider profile · identity verified
Phuc H Pham, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PHOENIX, AZ · NPI 1760456487
Verified facts
What the public records show
CMS Open Payments records show Phuc H Pham, M.D. received $694.88 in general payments during 2025 across 29 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $113.46 | 16.3% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $112.94 | 16.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $109.81 | 15.8% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $64.33 | 9.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.18 | 6.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.57 | 6.0% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$33.12 | 4.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.77 | 4.6% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $24.75 | 3.6% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.71 | 3.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.47 | 3.4% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $18.64 | 2.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.03 | 2.6% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $17.90 | 2.6% | 1 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $17.20 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $694.88 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $113.46 | 4 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $112.94 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $109.81 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $64.33 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $41.57 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.57 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $33.12 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.77 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $26.02 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $26.02 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $23.71 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 52 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 106 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
29 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
106 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
52 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 576 | 180 |
| Levothyroxine Sodium | Levothyroxine Sodium | 292 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 266 | 83 |
| Losartan Potassium | Losartan Potassium | 260 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 246 | 85 |
| Metformin Hcl | Metformin Hcl | 226 | 74 |
| Lisinopril | Lisinopril | 198 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 178 | 57 |
| Simvastatin | Simvastatin | 178 | 47 |
| Gabapentin | Gabapentin | 163 | 50 |
| Omeprazole | Omeprazole | 155 | 60 |
| Alendronate Sodium | Alendronate Sodium | 130 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 36 |
| Donepezil Hcl | Donepezil Hcl | 111 | 28 |
| Ozempic | Semaglutide | 106 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 47 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 29 |
| Mirtazapine | Mirtazapine | 85 | 23 |
| Glipizide Er | Glipizide | 84 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 26 |
| Finasteride | Finasteride | 79 | 23 |
| Allopurinol | Allopurinol | 75 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 21 |
| Trazodone Hcl | Trazodone Hcl | 71 | 23 |
| Famotidine | Famotidine | 65 | 30 |
| Farxiga | Dapagliflozin Propanediol | 64 | 18 |
| Alprazolam | Alprazolam | 63 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 25 |
| Prednisone | Prednisone | 62 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 22 |
| Trulicity | Dulaglutide | 55 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 54 | 14 |
| Eliquis | Apixaban | 52 | 17 |
| Furosemide | Furosemide | 52 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | suppressed |
| Meloxicam | Meloxicam | 49 | 22 |
| Jardiance | Empagliflozin | 48 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 14 |
| Tramadol Hcl | Tramadol Hcl | 46 | 20 |
| Azithromycin | Azithromycin | 45 | 42 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 12 |
| Metformin Hcl Er | Metformin Hcl | 36 | 12 |
| Carvedilol | Carvedilol | 35 | 11 |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Valsartan | Valsartan | 33 | 11 |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Atenolol | Atenolol | 31 | 11 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Prolia | Denosumab | 29 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 26 |
| Celecoxib | Celecoxib | 28 | 11 |
| Estradiol | Estradiol | 28 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | 11 |
| Cephalexin | Cephalexin | 26 | 26 |
| Ipratropium Bromide | Ipratropium Bromide | 26 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | 14 |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 13 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 19 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Baclofen | Baclofen | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $694.88 · 29 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AIRSUPRA, AREXVY, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, EVKEEZA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, Fluad, Flucelvax, GARDASIL 9, JARDIANCE, NURTEC ODT, Nayzilam, OTEZLA, Ozempic, PYRUKYND, REPATHA, Rybelsus, SHINGRIX, SX-ONE MICROKNIFE, SYMPLICITY G3, TRELEGY ELLIPTA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error